Johnson & Johnson $JNJ Stock Bought by Wedmont Private Capital

Wedmont Private Capital lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 22.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 41,616 shares of the company’s stock after acquiring an additional 7,564 shares during the quarter. Wedmont Private Capital’s holdings in Johnson & Johnson were worth $10,674,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of JNJ. Outlook Capital Management LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $28,000. Matrix Trust Co lifted its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares during the period. Montgomery Financial Services LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth $43,000. Hyposwiss Advisors SA purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at $42,000. Finally, Polaris Financial Partners purchased a new position in shares of Johnson & Johnson during the third quarter valued at $56,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. HSBC upped their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Bank of America reiterated a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Scotiabank reissued an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, TD Cowen boosted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $276.22.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $261.27 on Friday. The company has a market capitalization of $629.64 billion, a PE ratio of 30.27, a P/E/G ratio of 2.60 and a beta of 0.21. The company has a 50-day simple moving average of $265.83 and a two-hundred day simple moving average of $249.01. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same period last year, the business earned $2.77 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts expect that Johnson & Johnson will post 11.18 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra), its targeted oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis. Nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years, with responses sustained and a favorable safety profile. The results strengthen the potential of ICOTYDE as a future growth product and were presented at a dermatology meeting. Johnson & Johnson ICOTYDE two-year psoriasis data
• Positive Sentiment: Guggenheim reaffirmed a Buy rating, while Morgan Stanley also issued a Buy rating. The positive analyst view reflects JNJ’s diversified healthcare portfolio, drug launches and defensive dividend appeal. Guggenheim reaffirms Buy rating
• Positive Sentiment: Several investment commentaries continue to present JNJ as a dividend-focused healthcare holding, emphasizing its long record of dividend growth and relatively dependable cash generation compared with higher-yielding but riskier peers. Healthcare Dividend Aristocrats
• Neutral Sentiment: JNJ is approaching its third-quarter earnings report with expectations for continued strength in pharmaceuticals and newer product launches. Investors will focus on revenue growth, guidance and the pace of Stelara-related sales erosion.
• Negative Sentiment: Analysts warn that biosimilar competition for Stelara and challenges in the MedTech business could weigh on near-term growth, limiting the impact of otherwise strong drug performance. J&J stock ahead of Q3 earnings
• Negative Sentiment: Upcoming patent expirations for Imbruvica and Darzalex create a longer-term “patent cliff” risk, potentially pressuring pharmaceutical revenue unless pipeline products and acquisitions offset lost exclusivity. J&J patent cliff analysis
• Negative Sentiment: Boston Scientific has sued JNJ subsidiary Atraverse over alleged patent infringement involving the Hotwire cardiology device, seeking damages and an injunction. The financial impact is uncertain but adds legal and competitive risk to the MedTech segment. Boston patent lawsuit against J&J subsidiary

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.